Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MBX Biosciences, Inc. - Common Stock (NQ:MBX)

12.16 +1.03 (+9.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MBX Biosciences, Inc. - Common Stock

Mbx Biosciences (MBX) Q2 Loss Widens 22%
Via The Motley Fool
This Lionsgate Studios Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity. 
Via Benzinga
Earnings Scheduled For February 13, 2025
 
Via Benzinga
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week
These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Topics Economy
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
How Richard DiMarchi Revolutionized Diabetes Treatment
Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi. 
Via Investor's Business Daily
MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action
MBX Biosciences reports Phase 1 trial results for MBX 1416, a GLP-1 receptor antagonist for post-bariatric hypoglycemia. Phase 2 starts in 2025. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For December 19, 2024
 
Via Benzinga
StandardAero Surges In Market Debut
Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at... 
Via Talk Markets
Topics Initial Public Offering
Trio Of Biotech IPOs Climb In Debut
A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.